We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 3

2.
Figure 2

Figure 2. Serum TFV and TFV-DP concentration versus time.. From: MTN-001: Randomized Pharmacokinetic Cross-Over Study Comparing Tenofovir Vaginal Gel and Oral Tablets in Vaginal Tissue and Other Compartments.

Serum TFV (panel A) and PBMC TFV-DP (panel B) concentration versus time plots are shown for the observed 8 hour interval following a dose in clinic according to dosing regimen. Median with asymmetric upper and lower quartiles is shown. Values are only for the 70 US participants where all 6 PK samples were collected.

Craig W. Hendrix, et al. PLoS One. 2013;8(1):e55013.
3.
Figure 3

Figure 3. Boxplots of TFV and TFV-DP concentrations by anatomic site.. From: MTN-001: Randomized Pharmacokinetic Cross-Over Study Comparing Tenofovir Vaginal Gel and Oral Tablets in Vaginal Tissue and Other Compartments.

Side-by-side boxplots of end-of-period visit data for all participants by anatomic site and dosing regimen are shown. Each box indicates the interquartile range with center bar as median and whiskers 1.5 times the quartile. *Lower quartile (LQ) is below the limit of quantitation (LOQ), only median and above are shown. **Median is below LOQ, so the median of values above the LOQ are shown as a single bar. X-axis key: anatomic location, PBMC peripheral blood mononuclear cells, CVL cervicovaginal lavage, ECC endocervical cytobrush; drug moiety, TFV tenofovir, TFV-DP tenofovir diphosphate; sample timing, Cmax peak concentration following dose at clinic visit, Cpre-dose concentration prior to dose at clinic visit, Call pools values from all participants regardless of scheduled time relative to dose.

Craig W. Hendrix, et al. PLoS One. 2013;8(1):e55013.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk